Navigation Links
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Date:2/3/2010

al SB-509-901 in moderately severe DN.
  • Prosecution of a Phase 1 clinical trial of a ZFN-based therapeutic in subjects with recurrent or refractory glioblastoma by Sangamo's collaborators at City of Hope.
  • Continued prosecution of Sangamo's Phase 1 trial of SB-728-T for HIV/AIDS and of the SB-728-T Phase 1 study by collaborators at the University of Pennsylvania School of Medicine.
  • Data Presentations from the Company's Phase 2 clinical trials of SB-509 for ALS (SB-509-801) and for severe DN (SB-509-701B).
  • Data Presentation from the SB-728-T– HIV / AIDS program.

  • Business - Strategic Collaborations & Enabling Technology Agreements

    • Achievement of milestones and royalties in agreement with Sigma-Aldrich.
    • Achievement of commercial sublicenses and milestones in agreement with Dow AgroSciences.
    • Pursue strategic partnerships in ZFP Therapeutics including SB-509.
    • Continue to present and publish data from research collaborations in ZFP-platform enabled biology.

    Financials and Operations

    • Maintain year-end 2010 cash and investments balance of at least $60.0 million.

    Conference Call

    Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm.  A repla
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
    2. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
    3. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
    4. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
    5. Sangamo Announces Pricing of Public Offering of Common Stock
    6. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
    7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
    8. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
    9. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
    10. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
    11. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... The Medical Innovation Impact Index (MI3), a new ... innovation, has been developed at the Initiative for ... ( FDU ) Rothman Institute of Innovation and Entrepreneurship. ... FDA (Food & Drug Administration) draft guidance documents and ... medical devices. , “The main impediment to innovation ...
    (Date:5/26/2015)... Regenestem Network has announced the grand opening ... Argentina. The clinic will be lead by Silvina Pastrana, ... a multidisciplinary team of medical professionals who specialize in ... office. , The new Regenestem Network members plan ... in cellular therapies, and establish Regenestem protocols to isolate ...
    (Date:5/26/2015)... Kalifornien und HILDEN, Deutschland, May 26, 2015 ... Insight ®   ermöglicht ... die Erstellung dazugehöriger Berichte; Vorstellung auf den ... QIAGEN N.V. (NASDAQ: QGEN ; ... Markteinführung von QIAGEN Clinical Insight ® ...
    (Date:5/26/2015)... 2015   Intrexon Corporation (NYSE: XON ), ... Frost , Ph.D., Senior Vice President and Head of Intrexon,s ... Conference on Wednesday, June 3 rd , at 1:30 p.m. ... York City . About Intrexon Corporation ... Bioindustrial Revolution with Better DNA ™ to create biologically-based ...
    Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
    ... continue to have access to ZEVALIN(R) and other novel ... ... New Medicare legislation,passed by the House and Senate extends the ... and Medicaid,Services (CMS) had implemented new hospital outpatient reimbursement rates,for ...
    ... (Nasdaq: ALXA ) announced today that it has ... Directors. Dr. Barron is currently,Senior Vice President, Development and ... organization, which is responsible for,pre-clinical, clinical and post-approval activities., ... clinical scientist and was,promoted in 2002 to Vice President ...
    ... Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... chaperones for the treatment of human,genetic diseases, ... Phase 2 clinical trials of Amigal(TM) (migalastat ... Amigal is being developed in,partnership with Shire ...
    Cached Biology Technology:House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 2House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels 3Alexza Elects Dr. Hal V. Barron to Its Board of Directors 2Alexza Elects Dr. Hal V. Barron to Its Board of Directors 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 2Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 3Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 4Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 5Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease 6
    (Date:4/27/2015)... -- For more than four decades, AUVSI,s Unmanned Systems ... worldwide event for the unmanned land, sea, and air ... any local, national, or trade news organization interested in ... current applications of unmanned technologies. The conference will explore ... industry, and how it will soon impact the lives ...
    (Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
    (Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
    Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
    ... Tampa, Fla. (Mar. 12, 2009) A study to ... from a combination of autologous (patient self-donated) stem cell ... of ) oxygen treatment (HBO) before and after ASC ... glycemic control" along with "reduced insulin requirements." The combination ...
    ... a profound role in regulating global climate. But the ... have long struggled to accurately measure their composition, size, ... new satellite instrument developed by NASA scientists, the Aerosol ... Some types of small aerosols -- such as black ...
    ... software developed with help from the Wildlife Conservation Society ... by creating a three-dimensional model using photos taken by ... of the journal Biology Letters , may also ... The new software, developed by Conservation Research Ltd., creates ...
    Cached Biology News:Stem cell infusion and hyperbaric oxygen treatment improve islet function in diabetes 2New aerosol observing technique turns gray skies to blue 2New aerosol observing technique turns gray skies to blue 3New aerosol observing technique turns gray skies to blue 4Tracking tigers in 3-D 2
    ... is an optical unit that can be ... Dyad Disciple gradient-capable thermal cycler (purchased separately). ... shuttle that contains four LEDs for fluorescence ... 620-650 nm) and two filtered photodiodes for ...
    ... (LCM) is the method of choice for ... the only instrument to offer both LCM ... UV Laser Cutting provides unprecedented ... and capturing large numbers of cells. , ...
    ... highly sensitive laser confocal systems designed for ... scanners that meet your expectations, differentiating between ... optimizing the signal on the bottom as ... range for increased sensitivity. Results with VersArray ...
    Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
    Biology Products: